Plain-English translation of NCT06464367 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Migraine research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
Researchers have noticed that people with migraines seem to get lasting relief after taking , a psychedelic substance. This study wants to understand *why* that happens by measuring changes in the brain, inflammation markers, sleep, and daily activity rhythms. Participants will take either or an active placebo, then undergo brain scans and other tests to help researchers figure out which parts of the treatment might be reducing headaches.
Many migraine drugs don't work well for everyone, and migraines can be severely disabling. Early observations suggest this medication might offer longer-lasting relief than current options, but doctors don't yet know how or why it works — so this study aims to unlock those answers.
You likely qualify if…
You likely don't qualify if…
You will visit Yale University for testing before and one week after receiving either the medication or placebo. During your visits, you'll have brain imaging scans (MRI and PET), blood tests, sleep monitoring, and activity tracking. You'll take a single dose of the treatment and then return for follow-up assessments to measure how your brain, inflammation levels, and sleep have changed. The entire study spans roughly 2 weeks of your time.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
United States